Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
NNC 38-1049
Cat. No.:
OB0425LY-063
Appearance:
Solid
Purity:
99.84%
Identity:
Confirmed by NMR and LC-MS.
Size:
Add to basket
Product Overview
Description:
NNC 38-1049 is a compound that targets diabetes and obesity and is a GLP-1 receptor agonist.
Synonyms:
757183-18-9; NNC-38-1049; NNC 38-1049; 1-(4-Chlorophenyl)-4-(4-cyclopentyl-1-piperazinyl)-1,4-butanedione; 1-(4-Chlorophenyl)-4-(4-cyclopentylpiperazin-1-yl)butane-1,4-dione; Piperazine, 1-(4-(4-chlorophenyl)-1,4-dioxobutyl)-4-cyclopentyl-
CAS No.:
757183-18-9
Compound CID:
9798429
Formula:
C19H25ClN2O2
Formula Weight:
348.87
Specification
Target:
Histamine receptor
Pathway:
GPCR/G protein; Immunology/Inflammation; Neuronal signaling
Solubility:
DMSO
Storage:
Storage at -20°C.
Applications:
NNC 38-1049 can be used to study the treatment of metabolic diseases, especially in regulating insulin secretion and improving glycemic control.
